MULTIPLE SCLEROSIS DRUG DRAGS ON
A NEW treatment for Multiple Sclerosis approved and registered
with the Therapeutic Goods Administration last month after more than 30
years of development may not be available in Australia for the
foreseeable future.
The antibody molecule alemtuzumab selectively targets proteins in
certain cells, changing the balance of the immune system in a way that
potentially reduces the activity of the disease.
For use by people with active relapsing MS, given as a five-day course of intravenous infusions followed by three
days of infusions one year later and is aimed as slowing the
accumulation of disabilities and reducing the frequency of relapses.
It is not recommended for patients with mild or inactive MS or those stable on their current therapy.
My Educational Video on MS and MS Trials
Post a Comment